Gene expression profiling of peripheral blood mononuclear cells during treatment with a gene-modified allogeneic tumor cell vaccine in advanced renal cell cancer: Tumor-induced immunosuppression and a possible role for NF-κB

2014 ◽  
Vol 136 (8) ◽  
pp. 1814-1826 ◽  
Author(s):  
Anne Flörcken ◽  
Michael Grau ◽  
Annette Wolf ◽  
André Weilemann ◽  
Joachim Kopp ◽  
...  
Keyword(s):  
Expression Profiling ◽  
Mononuclear Cells ◽  
Cell Cancer ◽  
Cell Vaccine ◽  
Tumor Cell Vaccine ◽  
Peripheral Blood Mononuclear ◽  
Blood Mononuclear Cells ◽  
Cancer Tumor ◽  
Allogeneic Tumor Cell ◽  
Advanced Renal Cell Cancer

scholarly journals Gene expression profiles in peripheral blood mononuclear cells of chronic heart failure patients

2009 ◽  
Vol 38 (3) ◽  
pp. 233-240 ◽  
Author(s):  
Claudia Cappuzzello ◽  
Monica Napolitano ◽  
Diego Arcelli ◽  
Guido Melillo ◽  
Roberta Melchionna ◽  
...  
Keyword(s):  
Gene Expression ◽  
Heart Failure ◽  
Chronic Heart Failure ◽  
Chemokine Receptor ◽  
Expression Profiling ◽  
Mononuclear Cells ◽  
Molecular Signature ◽  
Peripheral Blood Mononuclear ◽  
Control Subjects ◽  
Blood Mononuclear Cells

The present study was aimed at identifying chronic heart failure (CHF) biomarkers from peripheral blood mononuclear cells (PBMCs) in patients with ischemic (ICM) and nonischemic dilated (NIDCM) cardiomyopathy. PBMC gene expression profiling was performed by Affymetrix in two patient groups, 1) ICM ( n = 12) and 2) NIDCM ( n = 12) New York Heart Association (NYHA) III/IV CHF patients, vs. 3) age- and sex-matched control subjects ( n = 12). Extracted RNAs were then pooled and hybridized to a total of 11 microarrays. Gene ontology (GO) analysis separated gene profiling into functional classes. Prediction analysis of microarrays (PAM) and significance analysis of microarrays (SAM) were utilized in order to identify a molecular signature. Candidate markers were validated by quantitative real-time polymerase chain reaction. We identified a gene expression profiling that distinguished between CHF patients and control subjects. Interestingly, among the set of genes constituting the signature, chemokine receptor (CCR2, CX3CR1) and early growth response (EGR1, 2, 3) family members were found to be upregulated in CHF patients vs. control subjects and to be part of a gene network. Such findings were strengthened by the analysis of an additional 26 CHF patients ( n = 14 ICM and n = 12 NIDCM), which yielded similar results. The present study represents the first large-scale gene expression analysis of CHF patient PBMCs that identified a molecular signature of CHF and putative biomarkers of CHF, i.e., chemokine receptor and EGR family members. Furthermore, EGR1 expression levels can discriminate between ICM and NIDCM CHF patients.

Sign in / Sign up

Export Citation Format

Share Document